NVS — Recent News Coverage

BioCryst has achieved profitability while its rare-disease therapeutic Orladeyo generates material cash flows, creating a compelling acquisition target in the specialty pharma space. The achievement represents meaningfu…

Novartis and Dr. Reddy's have terminated their distribution and commercialization agreement in India, a routine contractual adjustment that reflects shifting strategic priorities in one of the world's largest pharmaceut…

Novonesis is consolidating its fermentation and yeast biotechnology platform through full acquisition of MicroBioGen, eliminating a joint venture structure. This move signals management confidence in the commercial traj…

Natco Pharma has filed a patent challenge against Novartis and Astex in the Delhi High Court, alleging that the two companies unlawfully secured dual patents for the same breast cancer drug invention—the Ribociclib mole…

ChrysCapital's majority acquisition of Novartis India represents a structural shift in the subsidiary's ownership and strategic direction, though limited direct implications for parent NVS's consolidated financials. The…

Novartis (NVS) demonstrated resilience in Q2 earnings with oncology strength offsetting headwinds in its Entresto franchise, a key cardiovascular asset. The reaffirmation of 2026 guidance signals management confidence i…

Novartis Q2 2026 earnings call represents a routine quarterly disclosure event with no material catalysts flagged in the available summary. The earnings call transcript itself is a standard reporting obligation that typ…

Novartis demonstrated revenue acceleration in Q2 driven by portfolio innovation, signaling that newer therapeutic launches are offsetting structural headwinds from generic erosion. This outcome validates the company's R…

Novartis (NVS) continues strategic portfolio expansion through the acquisition of Myricx Bio, signaling management confidence in antibody-drug conjugate (ADC) technology as a core growth vector. This inorganic approach …

Novartis announced a $1.5 billion acquisition of Myricx Bio, a UK-based biotechnology company, signaling continued aggressive pursuit of pipeline expansion in specialized therapeutic areas. This move reflects large-cap …

Sofinnova Partners announced the acquisition of its portfolio company Myricx Bio by Novartis (NVS) for up to $1.5 billion, comprising $1.1 billion in upfront cash and milestone-based contingent payments. This represents…

Novartis (NVS) has agreed to acquire Myricx Bio, a UK-based private biotech firm specializing in antibody-drug conjugates (ADCs) with novel N-myristoyltransferase inhibitor (NMTi) payloads. This strategic move signals N…

Novartis (NVS) faces structural headwinds from generic erosion in its core portfolio, prompting a downgrade to hold despite recent regulatory wins. The ITVISMA gene therapy approval represents a meaningful clinical achi…

JPM, NVS, and QCOM are featured in aggregate analyst coverage reports that synthesize sector-specific growth trajectories and forward catalysts. This type of multi-ticker roundup typically reflects scheduled earnings cy…

Novartis (NVS) has entered a strategic oncology partnership with Antares involving $105M upfront and contingent milestone payments reaching $1.8B. This structure reflects a long-term value-creation approach rather than …

Novartis AG (NVS) disclosed positive interim data from an experimental therapy targeting facioscapulohumeral muscular dystrophy (FSHD), a rare inherited neuromuscular disorder. The drug candidate, sourced through the co…

Novartis AG (NVS) has been identified as a constituent of a curated list of longevity and anti-aging stocks, signaling institutional attention toward the expanding gerontology biotech segment. The inclusion reflects mar…

Novartis has secured regulatory approval and market entry for Pluvicto in India, marking the nation's first approved radioligand therapy for advanced prostate cancer treatment. This represents a strategic geographic exp…